Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease.

"CONFLICT OF INTEREST STATEMENT J.J.N. reports personal fees and other support from Bayer AG, Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Proteomics International, and Dexcom outside the submitted work. R.Z.A. is supported by NIH research grants OT2HL161847, OT2OD032581, U24TR001608 and CDC project number 75D301-21-P-12254; and reports other support from Travere Therapeutics Inc. out of the submitted work, and personal fees from Boehringer Ingelheim; other support from Bayer AG, AstraZeneca, Novo Nordisk, The George Institute for Global Health, and CareDx, Inc. K.R.T. is supported by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, UM1AI109568 and CDC project number 75D301-21-P-12254. She has also received investigator-initiated grant support from Travere and Bayer Pharmaceuticals outside of the submitted work. She reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk and Travere; and speaker fees from AstraZeneca, Eli Lilly, and Novo Nordisk."

"NIH10.13039/100000002; CDC10.13039/100000030"